Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...

Related Keywords

Acta Oncologica ,Mark Erlander ,Joyce Allaire ,Van Cutsem ,James Levine ,Cardiff Oncology Inc ,Pdac Program ,Crc Program ,University Of Pittsburgh Medical Center ,Cardiff Oncology Expanded Access Program ,Prnewswire Cardiff Oncology Inc ,Beretta ,Nasdaq ,Exchange Commission ,European Society For Medical Oncology ,Dana Farber Cancer Institute ,European Society ,Medical Oncology ,Cardiff Oncology ,Expanded Access Program ,Pancreatic Ductal Adenocarcinoma ,Pittsburgh Medical Center ,Months Ended September ,Lancet Oncol ,Correspondence Lancet ,Med Oncol ,Spring Harb Perspect Med ,Looking Statements ,Private Securities Litigation Reform Act ,Oncology Contact ,